^
Association details:
| Biomarker: | NFE2L2 mutation + STK11 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | sirpiglenastat (DRP-104) (Glutamine antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DRACEN PHARMACEUTICAL’S DRP-104 GRANTED U.S. FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
Published date:
10/27/2020
Excerpt:
Dracen Pharmaceuticals...announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s novel glutamine antagonist DRP-104 for the treatment of advanced, previously treated non-small cell lung cancer (NSCLC) patients whose tumors express mutations in KEAP1, NFE2L2 and/or STK11.
